For Canadian cannabis companies, the industry offers plenty of international opportunities, and for as such the International Cannabis (TSXV:ICC) the story is no different; as such, the company announced on Monday (July 17), that it has been approved for the sale of recreational cannabis in Uruguay.
The actual product will be sold through the country’s approved network of sales, with only two non-medical products for adult-use available, sealed in 5-gram packaging with a $6.50 cost per unit.
In the company’s press release, ICC shared a report from the Institute of Regulation and Control of Cannabis (IRCCA), stating the company would be able to begin the sale of “psychoactive cannabis for non-medical use in pharmacies” by July 19.
Restrictions for the recreational cannabis market in Uruguay
Uruguay has taken significant steps forward when it comes to the legalization of cannabis and has served as a test base model for other markets to use as part of their own legalization path.
In April of this year, it became legal in Uruguay for consumers to buy cannabis in pharmacies. However, there is a vigorous regulation system for consumers to go through in order to legally obtain the product. According to CNBC, there is a national registry for only local residents to apply, and a monthly maximum of 40 gram per person.
“[V]endors can only sell the drug in 5-gram containers, although 10-gram containers are expected to be introduced later,” CNBC reported
Alejandro Antalich, CEO of ICC said the company would continue the construction of a CBD extraction laboratory in Uruguay, the project currently has an intended April 2018 date for its launch.
ICC has a 70,000 square foot greenhouse, entirely dedicated to the production of adult-use cannabis and it plans to increase the production of CBD dried flower to approximately 160 tons per year.
Recent market research from analyst Neal Gilmer at Mackie Research Capital indicated the company had a worthwhile return thanks to the potential of its expansion in the South American market. Gilmer stamped ICC with a “Tentative Buy” for his report in December of 2016.
At the close of trading on Monday, the company’s share price had increased 2.7 percent over a one-day trading period to reach $1.14. Year-to-date, shares of ICC are up 17.53 percent.
Don’t forget to follow us @INN_LifeScience and @INN_Cannabis for real-time news updates.
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.
Pineapple Express Delivery Partners with CannTrust to Offer Same-Day and Next-Day Delivery for estoraTM Medical Cannabis Patients in Ontario
Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products
World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario
American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.
Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.
Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.
As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.
A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.
BioHarvest Sciences Inc. Unveils the Unique Polyphenolic Content of Its Upcoming Olive-Based Nutraceutical
The product will include polyphenols known to have significant health benefits.
BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.